EMA allows emergency use of MSD's Covid-19 capsule treatment

MSD's capsule should be taken as early as possible after a Covid-19 diagnosis, within five days of symptoms beginning, the EMA instructs.


As Covid-19 cases soar in many places throughout Europe, the European Medicines Agency (EMA) has issued advice on Friday pertaining to the emergency use of MSD's Covid-19 capsule molnupiravir.

At the same time, the EMA announced that it was beginning a review of Pfizer's oral antiviral drug, which has received some interest recently.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs